Cullinan Oncology LLC Stock Math Transform Price Ceiling Movement

CGEM Stock  USD 13.49  -0.46  -3.30%   
This math transform tool runs Price Ceiling Movement transformation and companion studies for Cullinan Oncology. Signals here center on price transformations that reveal shifts in trend structure alongside volatility and performance references.

Transformation
This analysis covers sixty-one data points across the selected time horizon. Cullinan Oncology Price Ceiling Movement function is a real number to the largest previous price integer.

Cullinan Oncology Technical Analysis Modules

Most technical analysis of Cullinan Oncology help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Cullinan from various momentum indicators to cycle indicators. When you analyze Cullinan charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. The profile for Cullinan Oncology integrates fundamentals, price behavior, and sector exposure. Historical patterns suggest somewhat reduced sensitivity to broader economic swings. Cullinan Oncology has a market cap of 796.94 M, P/E of 5.23, ROE of -44.02%.

Methodology

Unless otherwise specified, financial data for Cullinan Oncology LLC is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cullinan (USA Stocks:CGEM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Cullinan Oncology LLC has active sell-side coverage. Source-validated coverage currently shows 12 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 6 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include HSBC Global Research, Wells Fargo Securities, Goldman Sachs, Guggenheim Securities, RBC Capital Markets, Citigroup, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Rifka Kats - Member of Macroaxis Editorial Board
Last reviewed on February 20th, 2026

Align your values with your investing style

With 796.94 Million market cap in the Biotechnology industry, Cullinan Oncology LLC works well as a smaller-cap core holding around which broader thematic baskets can be built. Anchoring a Biotechnology theme around Cullinan Oncology LLC at 796.94 Million can be tuned for upside participation or tighter downside control depending on Healthcare outlook.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Driverless Cars Idea
Driverless Cars
Invested few shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Hedge Favorites Idea
Hedge Favorites
Invested over 40 shares
Investor Favorites Idea
Investor Favorites
Invested few shares
ESG Investing Idea
ESG Investing
Invested few shares
Momentum Idea
Momentum
Invested over 40 shares
Disruptive Technologies Idea
Disruptive Technologies
Invested few shares
FinTech Idea
FinTech
Invested over 20 shares
Blockchain Idea
Blockchain
Invested few shares

More Resources for Cullinan Stock Analysis

A structured review of Cullinan Oncology LLC often starts with core financial statements and trend context. Cullinan Oncology's financial ratios translate raw accounting data into comparable profitability and efficiency signals. Selected reports below provide context for Cullinan Stock:
Cullinan Oncology has a market cap of 796.94 M, ROE of -44.02%. See Trending Equities for portfolio-level analysis. This includes a position in Cullinan Oncology LLC across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.
Cullinan Oncology P/E of 5.23 alongside ROE at -44.02% frames the starting point - the resources below add portfolio-level context that single-security analysis cannot provide alone. Within Healthcare, these signals frame what the supplemental analysis tools below should validate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
 Earnings Share
-3.32
 Return On Assets
-0.28
 Return On Equity
-0.44
Understanding Cullinan Oncology LLC includes distinguishing between market value and book value, where book value reflects Cullinan's accounting equity. Cullinan Oncology's market capitalization is 796.94 M. Cullinan Oncology P/B of 1.77 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 465.53 M. Value and price for Cullinan Oncology are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
It is useful to distinguish Cullinan Oncology's value from its trading price, which are computed with different methods. For Cullinan Oncology, key inputs include a P/E ratio of 5.23, a P/B ratio of 1.77, and ROE of -44.02%. By contrast, Cullinan Oncology market price reflects the level where buyers and sellers transact.